Literature DB >> 26092308

Influence of maternally-derived antibodies on live attenuated influenza vaccine efficacy in pigs.

Hyun Mi Pyo1, Magda Hlasny1, Yan Zhou2.   

Abstract

Vaccination during pregnancy is practiced in swine farms as one measure to control swine influenza virus (SIV) infection in piglets at an early age. Vaccine-induced maternal antibodies transfer to piglets through colostrum and stabilize the herd: however, maternally derived antibodies (MDA) interfere with immune response following influenza vaccination in piglets at the later stage of life. In addition, MDA is related to enhanced respiratory disease in SIV infection. Previously, we have developed a bivalent live attenuated influenza vaccine (LAIV) which harbors both H1 and H3 HAs. We demonstrated vaccination of this LAIV provided protection to homologous and heterologous SIV infection in pigs. In this study we aimed to investigate the influence of MDA on LAIV efficacy. To this end, SIV sero-negative sows were vaccinated with a commercial vaccine. After parturition, nursery piglets were vaccinated with LAIV intranasally or intramuscularly, and were then challenged with SIV. We report that MDA hampered serum antibody response induced by intramuscular vaccination but not by intranasal vaccination of the LAIV. Viral challenge in the presence of MDA caused exacerbated respiratory disease in unvaccinated piglets. In contrast, all LAIV vaccinated piglets were protected from homologous viral infection regardless of the route of vaccination and the presence of MDA. Our results demonstrated that LAIV conferred protection in the presence of MDA without inciting exacerbated respiratory disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Live attenuated influenza vaccine; Maternally derived antibodies; Swine influenza

Mesh:

Substances:

Year:  2015        PMID: 26092308     DOI: 10.1016/j.vaccine.2015.06.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Heterologous challenge in the presence of maternally-derived antibodies results in vaccine-associated enhanced respiratory disease in weaned piglets.

Authors:  Daniela S Rajao; Matthew R Sandbulte; Phillip C Gauger; Pravina Kitikoon; Ratree Platt; James A Roth; Daniel R Perez; Crystal L Loving; Amy L Vincent
Journal:  Virology       Date:  2016-02-11       Impact factor: 3.616

2.  Conserved HA-peptide NG34 formulated in pCMV-CTLA4-Ig reduces viral shedding in pigs after a heterosubtypic influenza virus SwH3N2 challenge.

Authors:  Marta Sisteré-Oró; Júlia Vergara-Alert; Thomas Stratmann; Sergi López-Serrano; Sonia Pina-Pedrero; Lorena Córdoba; Mónica Pérez-Maillo; Patrícia Pleguezuelos; Enric Vidal; Veljko Veljkovic; Joaquim Segalés; Jens Nielsen; Anders Fomsgaard; Ayub Darji
Journal:  PLoS One       Date:  2019-03-01       Impact factor: 3.240

3.  In Vivo Characterization of Avian Influenza A (H5N1) and (H7N9) Viruses Isolated from Canadian Travelers.

Authors:  Yao Lu; Shelby Landreth; Amit Gaba; Magda Hlasny; Guanqun Liu; Yanyun Huang; Yan Zhou
Journal:  Viruses       Date:  2019-02-23       Impact factor: 5.048

Review 4.  Impact of maternally derived immunity on immune responses elicited by piglet early vaccination against the most common pathogens involved in porcine respiratory disease complex.

Authors:  Núria Martínez-Boixaderas; Laura Garza-Moreno; Marina Sibila; Joaquim Segalés
Journal:  Porcine Health Manag       Date:  2022-03-16

Review 5.  Influenza A Virus in Swine: Epidemiology, Challenges and Vaccination Strategies.

Authors:  José Carlos Mancera Gracia; Douglas S Pearce; Aleksandar Masic; Monica Balasch
Journal:  Front Vet Sci       Date:  2020-09-22

6.  Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.

Authors:  Weihong Gu; Darling Melany D Madrid; Guan Yang; Bianca L Artiaga; Julia C Loeb; William L Castleman; Jürgen A Richt; John A Lednicky; John P Driver
Journal:  Dev Comp Immunol       Date:  2020-08-29       Impact factor: 3.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.